about
Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate VaccineCommunity Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine TrialsGenome-Wide Comparison of Medieval and Modern Mycobacterium lepraeThe Pneumonia Etiology Research for Child Health Project: a 21st century childhood pneumonia etiology studyCost-effectiveness of maternal influenza immunization in Bamako, Mali: A decision analysisUse of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study.The Burden of Cryptosporidium Diarrheal Disease among Children < 24 Months of Age in Moderate/High Mortality Regions of Sub-Saharan Africa and South Asia, Utilizing Data from the Global Enteric Multicenter Study (GEMS)Sanitation and Hygiene-Specific Risk Factors for Moderate-to-Severe Diarrhea in Young Children in the Global Enteric Multicenter Study, 2007-2011: Case-Control Study.Streptococcal pharyngitis in schoolchildren in Bamako, Mali.Microbiota that affect risk for shigellosis in children in low-income countriesDelayed 2009 pandemic influenza A virus subtype H1N1 circulation in West Africa, May 2009-April 2010.Genomic characterization of enteroaggregative Escherichia coli from children in MaliSeeking care for pediatric diarrheal illness from traditional healers in Bamako, Mali.Are variable-number tandem repeats appropriate for genotyping Mycobacterium leprae?Identification by PCR of non-typhoidal Salmonella enterica serovars associated with invasive infections among febrile patients in Mali.Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers.Household crowding, social mixing patterns and respiratory symptoms in seven countries of the African meningitis beltGlobal practices of meningococcal vaccine use and impact on invasive disease.Shigella isolates from the global enteric multicenter study inform vaccine development.Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study.Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine.Background rates of adverse pregnancy outcomes for assessing the safety of maternal vaccine trials in sub-Saharan Africa.Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, doubDifferences in patterns of high-risk human papillomavirus infection between urban and rural low-resource settings: cross-sectional findings from MaliEstimating the impact of human papillomavirus (HPV) vaccination on HPV prevalence and cervical cancer incidence in Mali.Methods for identifying Neisseria meningitidis carriers: a multi-center study in the African meningitis belt.Risk factors for high-risk human papillomavirus infection in unscreened Malian women.Genotypic analysis of invasive Streptococcus pneumoniae from Mali, Africa, by semiautomated repetitive-element PCR and pulsed-field gel electrophoresis.The causes of hospital admission and death among children in Bamako, Mali.A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis BeltStrategies for Coordination of a Serosurvey in Parallel with an Immunization Coverage Survey.Immunization Coverage Surveys and Linked Biomarker Serosurveys in Three Regions in Ethiopia.Naturally acquired and conjugate vaccine-induced antibody to Haemophilus influenzae type b (Hib) polysaccharide in Malian children: serological assessment of the Hib immunization program in MaliInvasive Nontyphoidal Salmonella Infections Among Children in Mali, 2002-2014: Microbiological and Epidemiologic Features Guide Vaccine Development.Willingness to Know the Cause of Death and Hypothetical Acceptability of the Minimally Invasive Autopsy in Six Diverse African and Asian Settings: A Mixed Methods Socio-Behavioural Study.Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in MaliNeisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal VaccinationHigher Tetanus Toxoid Immunity 2 Years After PsA-TT Introduction in MaliAntibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013.
P50
Q26778270-DB0260AE-06DD-4F7A-AF8D-00D65A6C5B90Q26778276-05976958-81FF-4344-8649-04EBEAA16A7EQ28137492-9B477A61-9E99-44B3-94AD-343B13DAEEE9Q28731424-26434B10-9936-4B85-AD98-8660AFFA86FEQ29247948-C35C8E9E-EE12-4C07-B919-2F84E9AB11F1Q30275836-DA38C605-4C7A-449E-BCD4-5500F45C1815Q30276745-70ED82D4-E867-4220-B00A-C66C9BA16E2CQ30276876-706F347D-7C3A-47F3-A9FE-3D4DD98F6164Q30301331-456D4762-7A39-46CB-ACE5-6DB6480AFCBCQ30408229-BA6C569A-7D4E-44EB-AE04-CFD05064D961Q30423834-73E0E4BE-3863-4F11-AEB5-8E65C6CBBF4AQ30428800-81882BA2-9050-48F6-A61F-DF5520CB661CQ30543267-7EF1ABF8-CF75-45B6-9C0C-EBA49E5A7675Q33336972-F2EE3C74-99FE-4EDD-BA9A-4193DE8CDD2DQ33541011-97D11DA7-FEBA-47FE-AB39-DEF965C3AF35Q33601899-64B6592E-0D78-4A06-BD74-58DFAE878B1EQ33837062-403FC6B4-4C66-447A-AF85-D63356398468Q33850840-A8F61BC1-EB6E-4BA2-B780-1900B6B6A111Q34202171-913CF129-0941-468D-AEB7-5D4DFF12727BQ34345075-063110B5-BB54-495C-AF4E-9D99E355E540Q34430626-0C7AA0AA-E1EF-489A-AE15-CE260605419CQ34441769-4660DA32-AB97-478A-89A3-EAC49A9B9CCFQ34500955-96075250-3787-4287-9974-4CEC6F65C4FDQ34578777-146380E2-13FA-4142-B718-802DD74E8F4EQ35019820-FDF5E4A7-E633-4439-AFA9-9F7E59DE94ECQ35032544-7083CEFD-1669-46A9-8020-A4B0D091BA01Q35569084-ECF2D0AA-A8DB-4117-889A-7863CA1B9208Q35690664-DF26721C-ED48-4598-876E-BD4FDFC20016Q35826028-7ED6916F-FC36-4EBB-AF5E-9946E2BD9726Q35922578-5273EF17-C6CD-433D-87F5-5D68B0295213Q35934056-FC91D84E-5B20-4E8A-A1E9-FF83FCB53D2BQ35943000-D507CE49-1CE8-40FD-9DBF-2EA99915B555Q36005810-BD3644FD-4E44-4E8F-8CDF-A0F842B470FFQ36133462-B34D8A5A-C8CC-4068-A732-6CD1F758D39DQ36201016-D252B4EB-4087-4A8F-9244-DC62E653A243Q36265001-F456D350-0C9B-4F39-BE20-7AB468DD771CQ36265012-C351CF4D-501A-492E-BC2C-C92DC190F163Q36265027-8E2DB394-B510-4C98-9681-2474E40A4859Q36265032-EACA862A-17FB-44FA-908B-67D02FB30C13Q36265065-DFC6C9E0-2DDC-4C68-A7EA-C5E6420D36AD
P50
description
infectious disease epidemiolog ...... Development in Mali (CVD-Mali)
@en
wetenschapper
@nl
name
Samba Sow
@en
Samba Sow
@nl
type
label
Samba Sow
@en
Samba Sow
@nl
altLabel
SO Sow
@en
Samba O. Sow
@en
Samba Ousmane Sow
@en
prefLabel
Samba Sow
@en
Samba Sow
@nl
P106
P108
P69
P108
P1412
P19
P21
P31
P496
0000-0002-6335-5066